DE69129989D1 - Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore - Google Patents

Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore

Info

Publication number
DE69129989D1
DE69129989D1 DE69129989T DE69129989T DE69129989D1 DE 69129989 D1 DE69129989 D1 DE 69129989D1 DE 69129989 T DE69129989 T DE 69129989T DE 69129989 T DE69129989 T DE 69129989T DE 69129989 D1 DE69129989 D1 DE 69129989D1
Authority
DE
Germany
Prior art keywords
polypeptide
maligner
tumors
treating
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69129989T
Other languages
English (en)
Other versions
DE69129989T2 (de
Inventor
Pierre Chambon
Marie-Paule Kieny
Richard Lathe
Mara Hareuveni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of DE69129989D1 publication Critical patent/DE69129989D1/de
Publication of DE69129989T2 publication Critical patent/DE69129989T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
DE69129989T 1990-10-23 1991-10-23 Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore Expired - Lifetime DE69129989T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9013101A FR2668064B1 (fr) 1990-10-23 1990-10-23 Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
PCT/FR1991/000835 WO1992007000A1 (fr) 1990-10-23 1991-10-23 Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne

Publications (2)

Publication Number Publication Date
DE69129989D1 true DE69129989D1 (de) 1998-09-17
DE69129989T2 DE69129989T2 (de) 1999-04-08

Family

ID=9401474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129989T Expired - Lifetime DE69129989T2 (de) 1990-10-23 1991-10-23 Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore

Country Status (12)

Country Link
US (3) US5861381A (de)
EP (1) EP0554344B1 (de)
JP (1) JP3195958B2 (de)
AT (1) ATE169640T1 (de)
CA (1) CA2094705C (de)
DE (1) DE69129989T2 (de)
DK (1) DK0554344T3 (de)
ES (1) ES2121791T3 (de)
FR (1) FR2668064B1 (de)
HK (1) HK1012841A1 (de)
SG (1) SG96535A1 (de)
WO (1) WO1992007000A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000026340A2 (en) * 1998-11-03 2000-05-11 The Penn State Research Foundation Novel nucleic acid molecules encoding opioid growth factor receptors
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
AU778701B2 (en) * 1999-09-08 2004-12-16 Imperial Cancer Research Technology Ltd MUC-1 derived peptides
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
CN1455680A (zh) * 2000-09-11 2003-11-12 达纳-法伯癌症协会有限公司 Muc1胞外域和癌症治疗组合物及方法
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
EP2386859B1 (de) 2000-11-27 2015-11-11 Minerva Biotechnologies Corporation Behandlung von Tumorerkrankungen
US20020110841A1 (en) * 2000-12-22 2002-08-15 KUFE Donald W. Regulation of cell growth by MUC1
WO2002078607A2 (en) * 2001-04-02 2002-10-10 The University Of Miami Mucin peptide with immunoenhancing properties
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
JP3854905B2 (ja) * 2002-07-30 2006-12-06 株式会社 日立ディスプレイズ 液晶表示装置
JP2007531505A (ja) * 2002-11-27 2007-11-08 ミネルバ バイオオテクノロジーズ コーポレーション 癌（ｍｕｃ１）の診断および治療のための技術および組成物
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
DK1944318T3 (da) 2003-07-21 2011-06-14 Transgene Sa Multifunktionelle cytokiner
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
AU2004299457B2 (en) 2003-12-12 2011-03-24 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
WO2005082458A1 (en) * 2004-02-23 2005-09-09 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
AU2007278756A1 (en) * 2006-07-25 2008-01-31 4G Vaccines Pty Ltd A cancer vaccine comprising a Mucin 1 (MUC1) T cell epitope-derived peptide
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
AU2010205717A1 (en) 2009-01-13 2010-07-22 Transgene Sa Use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
PL2382474T3 (pl) 2009-01-20 2015-08-31 Transgene Sa Rozpuszczalny ICAM-1 jako biomarker do prognozowania odpowiedzi terapeutycznej
NZ595290A (en) 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
MX2012000979A (es) 2009-07-21 2012-06-08 Transgene Sa Composición enzimática para la digestión de embriones de pollo.
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
US10517943B2 (en) 2014-12-01 2019-12-31 Transgene S.A. Stable liquid vaccinia virus formulations
CN107660213B (zh) 2015-02-10 2023-01-13 米纳瓦生物技术公司 人源化抗MUCl＊抗体
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN112512560A (zh) 2018-03-07 2021-03-16 特兰斯吉恩股份有限公司 副痘病毒属载体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
AU1103988A (en) * 1987-01-07 1988-07-27 Imperial Cancer Research Technology Limited Probe
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
SE459115B (sv) * 1987-10-08 1989-06-05 Gas Control Equipment Ab Anordning i ventil foer gasbehaallare
WO1990005142A1 (en) * 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
JPH02273195A (ja) * 1988-11-17 1990-11-07 Univ Melbourne ヒト多型性上皮ムチンと反応するモノクローナル抗体
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Also Published As

Publication number Publication date
DE69129989T2 (de) 1999-04-08
EP0554344B1 (de) 1998-08-12
FR2668064B1 (fr) 1994-12-16
US5861381A (en) 1999-01-19
DK0554344T3 (da) 1999-05-17
FR2668064A1 (fr) 1992-04-24
SG96535A1 (en) 2003-06-16
EP0554344A1 (de) 1993-08-11
JP3195958B2 (ja) 2001-08-06
CA2094705A1 (fr) 1992-04-24
WO1992007000A1 (fr) 1992-04-30
HK1012841A1 (en) 1999-08-06
US6203795B1 (en) 2001-03-20
JPH06502399A (ja) 1994-03-17
ATE169640T1 (de) 1998-08-15
ES2121791T3 (es) 1998-12-16
US6328956B1 (en) 2001-12-11
CA2094705C (fr) 2007-05-15

Similar Documents

Publication Publication Date Title
DE69129989T2 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
DE68925226T2 (de) Monoklonale Antikörper
Hauck et al. Control of carcinoembryonic antigen gene family expression in a differentiating colon carcinoma cell line, Caco-2
YU46189B (sh) Monoklonska antitela i antigen za karcinome pluća čoveka koji ne pripadaju tipu "malih ćelija"
GB2278357B (en) Humanised antibodies directed against A33 antigen
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
ATE234918T1 (de) Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
CA2308007A1 (en) Enhancer for antibody to lymphocytic tumors
DE69019410T2 (de) Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen.
ES8600518A1 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
Hanauske et al. Assessment of biological activity of linear α-transforming growth factor and monospecific antibodies to α-transforming growth factor and linear α-transforming growth factor
DE3786695T2 (de) Tumorassoziiertes Antigen.
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.
MX9705445A (es) Anticuerpos monoclonales anti-cd6 y su usos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition